Search

Zealand Pharma A-S

Fechado

511.2 1.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

494.9

Máximo

514.4

Indicadores-chave

By Trading Economics

Rendimento

7.9B

7.6B

Vendas

9.1B

9.1B

P/E

Médio do Setor

5.498

35.739

EPS

105.61

Margem de lucro

83.335

Funcionários

424

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+25.15% upside

Dividendos

By Dow Jones

Próximos Ganhos

13 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

12B

36B

Abertura anterior

509.25

Fecho anterior

511.2

Zealand Pharma A-S Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de out. de 2025, 08:54 UTC

Grandes Movimentos do Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

12 de mar. de 2025, 09:23 UTC

Grandes Movimentos do Mercado

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 de dez. de 2024, 09:22 UTC

Grandes Movimentos do Mercado

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 de mar. de 2025, 16:34 UTC

Principais Notícias

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 de mar. de 2025, 08:18 UTC

Conversa de Mercado

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Zealand Pharma A-S Previsão

Preço-alvo

By TipRanks

25.15% parte superior

Previsão para 12 meses

Média 270.582 DKK  25.15%

Máximo 270.568 DKK

Mínimo 270.568 DKK

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Zealand Pharma A-S - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

0

Comprar

1

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
help-icon Live chat